

REPRINT FROM OCTOBER 12, 2017

## EMERGING COMPANY PROFILE

# CHEMO-PROOF T CELLS

By Lauren Martz, Senior Writer

T cell therapies have shown unprecedented efficacy in hematologic malignancies, but haven't produced the same results in solid tumors and have dangerous toxicities. By combining engineered, drug-resistant  $\gamma\delta$  T cells with chemotherapy, [Incysus Ltd.](#) has hit upon a strategy that may be safer and more effective against solid tumors than conventional T cell therapies.

The  $\alpha\beta$  T cells most T cell therapies use are antigen-specific and may not eliminate the entire tumor. Incysus relies on  $\gamma\delta$  T cells because they do not require antigen processing to detect target cells, and they penetrate and kill solid tumors more effectively than  $\alpha\beta$  cells.

" $\gamma\delta$  T cells are like a bridge between the innate and adaptive immune response. They can kill like natural killer cells, then become antigen-presenting cells when activated," said Incysus CEO and co-founder William Ho.

According to Ho, one reason T cell therapies fail is that large numbers of the cells are destroyed by the immunosuppressive tumor microenvironment before they reach the tumor. Chemotherapy can kill Tregs, making that hostile environment penetrable, but it kills effector T cells as well.

To overcome the problem, Incysus creates  $\gamma\delta$  T cells that are chemotherapy-resistant. Using its Drug Resistant Immunotherapy (DRI) technology, the newco engineers allogeneic or autologous  $\gamma\delta$  T cells to express [MGMT](#), a DNA damage repair protein responsible for chemo resistance in cancers. It uses only  $\gamma\delta$  T cells from the  $V\delta 2$  subset because they are all interferon-producing cells with antitumor properties; the  $V\delta 1$  subset contains both interferon-producing and immunosuppressive lineages.

"We hijack a tumor's own resistance mechanisms and genetically engineer them into  $\gamma\delta$  T cells so they can survive co-dosing with high dose chemo," Ho said. Chemotherapy shrinks the tumor and kills Tregs, enabling the MGMT-expressing cells to penetrate the tumor and eliminate the remaining cancer cells.

The modified  $\gamma\delta$  T cells have two additional advantages: all cancer cells express the [NKG2D](#) ligands that  $\gamma\delta$  cells target,

**INCYSUS LTD.**, Hamilton, Bermuda

**Technology:** Drug-resistant  $\gamma\delta$  T cells delivered in combination with chemotherapy

**Disease focus:** Cancer

**Clinical status:** Preclinical

**Founded:** 2016 by William Ho, Lawrence Lamb and H. Trent Spencer

**University collaborators:** University of Alabama at Birmingham

**Corporate partners:** None

**Number of employees:** 1

**Funds raised:** Undisclosed

**Investors:** Undisclosed

**CEO:** William Ho

**Patents:** One issued covering the combination of chemotherapy with immune cells, including  $\gamma\delta$  T cells and NK cells

and chemotherapy up-regulates those ligands; and  $\gamma\delta$  T cells don't produce pro-inflammatory [IL-6](#) and so are unlikely to cause cytokine storms, making them safer than  $\alpha\beta$  T cell therapies.

At the 2017 [American Association for Cancer Research \(AACR\)](#) conference, Incysus presented data showing that in a mouse model of glioblastoma, 80% of animals simultaneously treated with its  $\gamma\delta$  T cells and temozolomide survived through the 150 day study, whereas all mice treated with either therapy alone died. The combination also increased survival in mice with temozolomide-resistant glioblastomas compared with temozolomide alone.

Incysus plans to submit an IND for its autologous  $\gamma\delta$  T cells plus temozolomide in glioblastoma by early next year.

While the newco ultimately plans to test allogeneic  $\gamma\delta$  T cells in solid tumors as well, its first trial of allogeneic cells will be in a more established indication. The newco submitted an IND for allogeneic  $\gamma\delta$  T cells in leukemia or lymphoma patients undergoing stem cell transplantation last month, and hopes to begin a Phase I/II trial early in 2018.

Incysus is in partnering discussions with undisclosed entities for both programs, and has begun raising funds in a series A round.

According to Ho, Incysus was launched last year with a seed round in the low single-digit millions, based on work from Emory University, the University of Alabama at Birmingham and Children's Healthcare of Atlanta Inc.

At least four other companies — GammaDelta Therapeutics Ltd., Adicet Bio Inc., Gadeta B.V. and Lymphocyte Activation Technologies S.A. — have  $\gamma\delta$  T cell-based therapies in preclinical development. According to Ho, no other companies have engineered drug-resistant  $\gamma\delta$  T cells. **■**

---

#### COMPANIES AND INSTITUTIONS MENTIONED

Adicet Bio Inc., Menlo Park, Calif.

American Association for Cancer Research (AACR), Philadelphia, Pa.  
Children's Healthcare of Atlanta, Atlanta, Ga.  
Emory University, Atlanta, Ga.  
Gadeta B.V., Utrecht, the Netherlands  
GammaDelta Therapeutics Ltd., London, U.K.  
Incysus Ltd., Hamilton, Bermuda  
Lymphocyte Activation Technologies S.A., Cantanhede, Portugal  
University of Alabama at Birmingham, Birmingham, Ala.

---

#### TARGETS

IL-6 - Interleukin-6  
MGMT - O6-alkylguanine alkyltransferase  
NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1

## BIOCENTURY INC.

---

### NEWSROOM

pressreleases@biocentury.com

#### SAN CARLOS, CA

+1 650-595-5333; Fax: +1 650-595-5589

#### CHICAGO

+1 312-755-0798; Fax: +1 650-595-5589

#### WASHINGTON, DC

+1 202-462-9582; Fax: +1 202-667-2922

#### UNITED KINGDOM

+44 (0)1865-512184; Fax: +1 650-595-5589

All contents Copyright © 2016 BioCentury Inc. ALL RIGHTS RESERVED. All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc. No part of BioCentury or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury Inc., which may be requested from Reprints/Permissions at [www.biocentury.com](http://www.biocentury.com).

**Trademarks:** BioCentury<sup>®</sup>; BCIQ<sup>™</sup>; The BioCentury 100<sup>™</sup>; Because Real Intelligence is Hard to Find<sup>™</sup>; and The Clear Route to ROI<sup>™</sup> are trademarks of BioCentury Inc.

**Use of Images:** Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "About Us" tab on the Homepage at [www.biocentury.com](http://www.biocentury.com).

All information provided through BioCentury Inc.'s Publications, Video and Audio Content, and Websites is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of such information, makes no warranties regarding such information, and is not responsible for any investment, business, tax or legal decision made or action taken in reliance upon such information.